Modifying PEST for Psoriatic Arthritis Screening
A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")
- Plaque Psoriasis
- Psoriatic Arthritis
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Novartis Pharmaceuticals
- Enrolment target
- 502
- Started
- 23 January 2025
- Main results due
- 31 December 2026
- Study sites
- 30
- Registry updated
- 28 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- Healthy volunteers can take part.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Key inclusion criteria: 1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment. 2. Adult patients at the time of informed consent signature 3. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions 4. Residents of Canada Key exclusion criteria: 1. Patients who have previously screened positive for PsA through PEST. 2. Patients who have been diagnosed with PsA. 3. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis) 4. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Study sites(30)
Novartis Investigative Site
Calgary, Alberta, Canada
Recruiting
Novartis Investigative Site
Edmonton, Alberta, Canada
Recruiting
Novartis Investigative Site
Edmonton, Alberta, Canada
Recruiting
Novartis Investigative Site
Kelowna, British Columbia, Canada
Recruiting
Novartis Investigative Site
Surrey, British Columbia, Canada
Recruiting
Novartis Investigative Site
Winnipeg, Manitoba, Canada
Recruiting
Novartis Investigative Site
Fredericton, New Brunswick, Canada
Recruiting
Novartis Investigative Site
Barrie, Ontario, Canada
Recruiting
Novartis Investigative Site
Greater Sudbury, Ontario, Canada
Recruiting
Novartis Investigative Site
Hamilton, Ontario, Canada
Recruiting
Novartis Investigative Site
Hamilton, Ontario, Canada
Recruiting
Novartis Investigative Site
Hamilton, Ontario, Canada
Recruiting
Novartis Investigative Site
London, Ontario, Canada
Recruiting
Novartis Investigative Site
London, Ontario, Canada
Recruiting
Novartis Investigative Site
Markham, Ontario, Canada
Recruiting
Novartis Investigative Site
Ottawa, Ontario, Canada
Recruiting
Novartis Investigative Site
Richmond Hill, Ontario, Canada
Recruiting
Novartis Investigative Site
Stoney Creek, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Waterloo, Ontario, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Québec, Quebec, Canada
Recruiting
Novartis Investigative Site
Québec, Quebec, Canada
Recruiting
Novartis Investigative Site
Ste-Foy, Quebec, Canada
Recruiting
Novartis Investigative Site
Verdun, Quebec, Canada
Recruiting
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada
Recruiting
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada
Recruiting
Showing 30 of 30 sites. 30 of the 30 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06382051. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me